Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10584
Title: Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Authors: Grossmann, Mathis;Premaratne, Erosha;Desai, Jayesh;Davis, Ian D
Affiliation: Endocrine Unit, Austin Health, Victoria, Australia.
Issue Date: 3-Apr-2008
Citation: Clinical Endocrinology 2008; 69(4): 669-72
Abstract: Sunitinib malate is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumours. Hypothyroidism has been observed in patients treated with sunitinib, but the mechanism whereby sunitinib induces hypothyroidism is unknown.To describe a series of six patients who developed thyrotoxicosis while on sunitinib for metastatic RCC.The study was conducted at Austin Health, a tertiary teaching hospital in Melbourne, Australia.Two patients developed severe thyrotoxicosis within 10 weeks after commencing sunitinib. In contrast, in the four patients who presented with later onset (16-30 weeks) thyrotoxicosis, the thyrotoxicosis was relatively mild, self-limiting and rapidly progressed to hypothyroidism. These patients experienced recurrent episodes of thyrotoxicosis in temporal relation to their cyclical sunitinib treatment. One patient had cytological evidence of lymphocytic thyroiditis.These findings suggest that sunitinib-induced hypothyroidism may be a consequence of preceding thyroiditis with associated transient thyrotoxicosis. As predictive factors are currently unknown, we suggest regular monitoring of thyroid function in all patients commenced on sunitinib. Clinicians treating patients with sunitinib or other similar kinase inhibitors should to be alerted to thyroid dysfunction as a potential toxicity of these agents.
Internal ID Number: 18394019
URI: http://ahro.austin.org.au/austinjspui/handle/1/10584
DOI: 10.1111/j.1365-2265.2008.03253.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/18394019
Type: Journal Article
Subjects: Adult
Antineoplastic Agents.adverse effects.therapeutic use
Carcinoma, Renal Cell.blood.drug therapy
Female
Humans
Indoles.adverse effects.therapeutic use
Kidney Neoplasms.blood.drug therapy
Male
Middle Aged
Pyrroles.adverse effects.therapeutic use
Thyrotoxicosis.blood.chemically induced.diagnosis
Thyrotropin.blood
Thyroxine.blood
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.